Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention

Med Lett Drugs Ther. 2018 Nov 5;60(1559):177-180.
No abstract available

Keywords: Aimovig; Ajovy; Botox; Corgard; Cymbalta; Depakote; Effexor; Emgality; Epival; Inderal; Lopressor; Qudexy; SNRIs; Tenormin; Topamax; Trokendi; adverse effects; amitriptyline; antidepressants; atenolol; beta blockers; botulinum toxin; dosage; duloxetine; efficacy; erenumab; fremanezumab; galcanezumab; metoprolol; migraine; nadolol; onabotulinumtoxinA; pregnancy; propranolol; safety; timolol; topiramate; tricyclic antidepressants; valproate; venlafaxine.

MeSH terms

  • Analgesics / administration & dosage*
  • Analgesics / adverse effects
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Calcitonin Gene-Related Peptide / antagonists & inhibitors*
  • Calcitonin Gene-Related Peptide / immunology
  • Calcitonin Gene-Related Peptide / metabolism
  • Humans
  • Injections, Subcutaneous
  • Migraine Disorders / diagnosis
  • Migraine Disorders / immunology
  • Migraine Disorders / metabolism
  • Migraine Disorders / prevention & control*
  • Signal Transduction / drug effects
  • Treatment Outcome

Substances

  • Analgesics
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • fremanezumab
  • galcanezumab
  • Calcitonin Gene-Related Peptide